Navigation Links
Advanced Life Sciences Announces Results of Shareholder Meeting and Provides Additional Information on Upcoming Advisory Committee Meeting
Date:4/2/2009

CHICAGO, April 2 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced that it held its Annual Meeting of Shareholders yesterday at its Woodridge headquarters.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

At the meeting, the shareholders elected Drs. Terry W. Osborn, Israel Rubinstein and Theron E. Odlaug to the Company's Board of Directors each for a term of three years and ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal year 2009. The shareholders also approved an amendment to the Company's articles of incorporation to increase the number of authorized shares from 65,000,000 to 125,000,000 including an increase in the number of authorized shares of common stock from 60,000,000 to 120,000,000.

In addition, the Company announced that the Anti-Infective Drugs Advisory Committee meeting has been confirmed for June 2, 2009, from 8 a.m. and 5 p.m. EDT. At the meeting, the Committee will discuss new drug application (NDA) 22-398, cethromycin oral tablets, sponsored by Advanced Life Sciences, for the proposed indication of outpatient treatment of adults with mild to moderate community-acquired pneumonia (CAP). The meeting, which will be open to the public, will be held at the Hilton Washington DC/Silver Spring at 8727 Colesville Rd. in Silver Springs, MD.

"We are eagerly preparing for this upcoming Advisory Committee meeting and we are looking forward to the opportunity to present not only the clinical safety and efficacy of our drug, but also the medical need for a product like cethromycin," said Dr. Michael Flavin, Chairman and CEO of Advanced Life Sciences.

About Cethromycin

In November 2008, the FDA filed the Company's NDA for cethromycin and established a target Prescription Drug User Fee Act (PDUFA) action date for the cethromycin NDA of July 31, 2009. Cethromycin has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria, certain Gram-negative bacteria and atypical organisms associated with respiratory tract infections. In in vitro tests, it appears to be effective against penicillin- and macrolide-resistant bacteria. Cethromycin has a mechanism of action that may slow the onset of future bacterial resistance. In addition to its utility in CAP, cethromycin is also being investigated as a broad spectrum biodefense countermeasure to combat agents of bioterror including anthrax, tularemia, plague and melioidosis. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer, respiratory diseases and biodefense. For more information, please visit us on the web at www.advancedlifesciences.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
3. Advanced Age No Bar to Liver Transplant
4. Oncologists are critical in managing psychiatric disorders in patients with advanced cancer
5. Advanced technologies aim to transform the coaching of top athletes
6. Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel
7. Advanced Life Sciences Joins NASDAQ Capital Market
8. Experimental drug shows promise in advanced kidney cancer
9. TCS Healthcare Technologies Announces Full Integration of Case Management Adherence Guidelines into Acuity Advanced Care(TM) System
10. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Demand ... at the East-coast edition of MarTech: The Marketing Tech Conference October 2–4, at ... more than 40 speakers — representing such thought-leading companies as JP Morgan ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... innovation, the company recently unveiled a redesigned website. The new site – still ... of building owners, architects, contractors and other industry users that Garland serves. , ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... gather for the National Athletic Trainers’ Association Annual Clinical Symposium and Expo. New ... It is also when Athletic Trainers are acknowledged by their peers with accolades ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Honey ... With Vaginas.” The goal is to ignite conversation via social media and word-of-mouth ... The brand has declared September “Humans with Vaginas” month, releasing a video celebrating ...
(Date:9/20/2017)... ... , ... The Centers for Medicare and Medicaid Services (CMS) stated in the ... only Worksheet S-10 to distribute Disproportionate Share Hospital (DSH) Uncompensated Care Payments over the ... on October 17, 2017 at 2 P.M. EST and uncover how you can ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017  Medical professionals ... and skills while treating their patients. Medical ... experience without involving patients. Simulation provides a ... can carry out procedures, refine techniques and ... Integration of new technology, such as augmented ...
(Date:9/5/2017)... Inc. has announced another milestone in their continued growth and success of the ... demands of customer engagements regionally.  ... office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office ... In addition ...
(Date:9/1/2017)... FISHERS, Ind. , Sept. 1, 2017  Explorers Like ... to capture America,s greatest aural experiences — and deliver these ... nature,s experience to help people feel and heal better. ... While nothing beats ... de-stress and refresh your mind, Life Environments™ is the next ...
Breaking Medicine Technology: